KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) EBT Margin (2016 - 2025)

West Pharmaceutical Services' EBT Margin history spans 17 years, with the latest figure at 20.06% for Q4 2025.

  • For Q4 2025, EBT Margin fell 196.0% year-over-year to 20.06%; the TTM value through Dec 2025 reached 19.55%, down 69.0%, while the annual FY2025 figure was 19.55%, 69.0% down from the prior year.
  • EBT Margin for Q4 2025 was 20.06% at West Pharmaceutical Services, down from 21.36% in the prior quarter.
  • Across five years, EBT Margin topped out at 29.46% in Q2 2022 and bottomed at 15.83% in Q1 2025.
  • The 5-year median for EBT Margin is 22.03% (2024), against an average of 22.61%.
  • The largest annual shift saw EBT Margin surged 981bps in 2021 before it tumbled -673bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 24.89% in 2021, then dropped by -27bps to 18.16% in 2022, then increased by 27bps to 22.98% in 2023, then dropped by -4bps to 22.02% in 2024, then fell by -9bps to 20.06% in 2025.
  • Per Business Quant, the three most recent readings for WST's EBT Margin are 20.06% (Q4 2025), 21.36% (Q3 2025), and 20.48% (Q2 2025).